The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 10, 2012
Filed:
Jun. 19, 2008
Jacek Jemielity, Warsaw, PL;
Ewa M. Grudzien-nogalska, Shreveport, LA (US);
Joanna Kowalska, Radom, PL;
Edward Darzynkiewicz, Izabelin, PL;
Robert E. Rhoads, Shreveport, LA (US);
Jacek Jemielity, Warsaw, PL;
Ewa M. Grudzien-Nogalska, Shreveport, LA (US);
Joanna Kowalska, Radom, PL;
Edward Darzynkiewicz, Izabelin, PL;
Robert E. Rhoads, Shreveport, LA (US);
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US);
University of Warsaw, Warsaw, PL;
Abstract
New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2'-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are 'anti-reverse cap analogs' (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog mGpppG.